Calpain inhibitors, a treatment for alzheimer’s disease
- 237 Downloads
Calpains modulate processes that govern the function and metabolism of proteins key to the pathogenesis of Alzheimer’s disease, including tau and amyloid precursor protein. Because activation of the calpain system might contribute to the impairment of synaptic transmission in Alzheimer’s disease, we are currently testing the hypotheses that a treatment with calpain inhibitors might restore normal cognition and synaptic transmission in a transgenic model of Alzheimer’s disease, the APP (K670N:M671L)/PS1(M146L) mouse. Findings derived from these studies will provide a novel approach to cognitive enhancement in Alzheimer’s disease.
Index EntriesAlzheimer’s disease calpain transgenic models hippocampus amyloid precursor protein presenilin 1
Unable to display preview. Download preview PDF.
- Masliah E. and Terry R. D. (1993) Role of synaptic pathology in the mechanisms of dementia in Alzheimer’s disease. Clin. Neurosci. 1, 192–198.Google Scholar
- Wang K. K. W. and Yuen P.-W. (1999) In: Calpain. Pharmacology and Toxicology of Calcium-Dependent Protease (Wang K. K. W. and Yuen P.-W., eds.), Taylor and Francis, Philadelphia, PA, 1999.Google Scholar
- Yoshi N., Ohgami T., Yamaguchi H., et al. (1999) Neuroprotective effects of a novel orally active reversible calpain inhibitor BDA-410. Soc. Neurosci. Abstr. 25, 136.8.Google Scholar